AK-Con-A (naphazoline ophthalmic)

Company
Akorn

Approval Status
Approved January 1996

Treatment for
antihistamine product

Areas
Eye Health / Ophthalmology

The over-the-counter version of AK-Con-A (naphazoline ophthalmic) has been approved as a vasoconstrictor/antihistamine product for opthalmic use. Naphazoline ophthalmic causes decongestion in the eye by constricting blood vessels in the eye. It also enlarges the pupil, and it reduces the amount of fluid in the eye in two ways: It reduces the production of fluid inside the eye, and it increases the amount of fluid that drains from the eye. It is used to relieve redness, burning, irritation, and dryness of the eye caused by wind, sun, and other minor irritants.

If you experience an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, face, or tongue; or hives); an irregular or fast heart rate; or high blood pressure (severe headache, blurred vision, or flushed skin you should immediately seek medical attention.

Less serious side effects include: burning, stinging, pain, or increased redness of the eye; tearing or blurred vision; headache; tremor; nausea; sweating; nervousness; dizziness; or drowsiness

Use naphazoline eye drops exactly as directed by your doctor, or follow the directions that accompany the package. If you do not understand these instructions, ask your doctor, pharmacist, or nurse to explain them to you.

Naphazoline ophthalmic can be used up to four times a day--every three to four hours. Do not use naphazoline ophthalmic more often or over a longer period than is recommended. Overuse can cause increased redness and irritation in the eye and can even lead to permanent damage

AK-Con-A (naphazoline ophthalmic) Drug Information

The AK-Con-A (naphazoline ophthalmic) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top